NCT Number: NCT05751941
Phase: Phase 2
Trial Summary: This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the trea – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Acronym:
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives